HOME >> BIOLOGY >> NEWS
New Hope On The Horizon For Patients With End-Stage Cardiovascular Disease

LOS ANGELES (August 3, 1998) -- Two experimental protocols are now available at Cedars-Sinai Medical Center for patients who have undergone multiple angioplasties or bypass procedures for coronary artery disease. Both procedures are non-surgical and show promise of improving quality of life for patients with end-stage cardiovascular disease. "The preliminary data are very encouraging," says P.K. Shah, M.D., Director of Cardiology at Cedars-Sinai.

Percutaneous Transmyocardial Laser Revascularization (PTMR)
According to Dr. Shah, Cedars-Sinai is one of only a few sites in the nation to offer Percutaneous Transmyocardial Laser Revascularization (PTMR). Using this procedure, cardiologists insert a laser catheter into the heart, creating multiple channels from the inside of the heart, out. These channels improve blood flow to heart muscles and stimulate growth of new blood vessels. To date, four patients have undergone PTMR at Cedars-Sinai. Norman Lepor, M.D., is the Principal Investigator on this study.

Vascular Endothelial Growth Factor Therapy (VEGF)
The second experimental protocol is Vascular Endothelial Growth Factor (VEGF) Therapy. VEGF is a genetically engineered compound that is normally produced in small amounts by the body and stimulates blood vessel growth. In this procedure, it is injected directly into the coronary artery to further stimulate blood vessel growth. The initial injection is followed by a series of three intravenous infusions -- one every three days. These subsequent infusions are done on an outpatient basis and take about four hours each. To date, two patients have been treated with VEFG Therapy at Cedars-Sinai. Dr. Shah is the Principal Investigator on this study.

# # #

To arrange an interview, please call 1-800-396-1002. Reporters, please note that this telephone number is exclusively for media use. Thank you for not publishing it.


'"/>

Contact: Sandy Van or Roberta Nichols
sandy@vancommunications.com
1-800-396-1002
Cedars-Sinai Medical Center
3-Aug-1998


Page: 1

Related biology news :

1. Bacteria Becoming Increasingly Resistant To Antibiotics, But New Vaccines Are On The Horizon
2. Patients cells from tumors, the immune system merged for customized cancer therapy
3. Patients give nod to kidney dialysis at home
4. Patients with atrial fibrillation undertreated for stroke risk
5. Patients with serious kidney disorder produce natriuretic peptides at above average rates
6. Drug treatment interruptions boost immune response to HIV in Patients
7. Study Suggests Vaccine Increases Survival In Ovarian And Breast Cancer Patients Following High-Dose Chemotherapy And Autologous Stem Cell Transplant
8. GenRISK Genetic Testing Program At Cedars-Sinai Medical Center Offers Patients New Hope In Confronting Disease
9. Oregon Scientists Discover A Second Blood-Brain Barrier; Important Finding For Patients With Brain Cancers And Neurological Disorders
10. In Colorado States Veterinary Foal Care Program, Student Volunteers Provide All-Night Care For Sick And Very Needy Patients
11. AIDS Virus May Evolve Differently In Cerebrospinal Fluid Compared With Blood In Some Patients, UCSF/Gladstone Research Finds

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... and Reentry. "Too often, too many ... and county jails are trying to tackle this ... and friends and family members. While significant steps are ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking event ... companies around the world, such as Illumina, HP and Qualcomm, and is ranked #1 in ... popularity is due to its new team building format, a way for teams to not ...
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics (OTCQB: ... personalized immune therapies for solid tumor cancers, today ... million financing it announced last Friday, March 17, ... several institutional investors securities totaling 28,843,692 shares, comprised ... and 10,000,000 shares of Class C Warrants pre-funded ...
(Date:3/23/2017)... 2017  GlobeImmune, Inc. today announced it has entered ... 12,835,490 shares of its common stock to NantCell, Inc., ... with the sale of its common stock, NantCell has ... to GlobeImmune 200,000 shares, an estimated $2.0 million in ... are pleased to enter into this strategic agreement with ...
(Date:3/23/2017)... ... 2017 , ... Ellen Matloff, president and CEO of My ... a 2017 Women of Innovation® finalist. Matloff will be among several women to ... dinner recognizes women accomplished in science, technology, engineering and math (STEM), along with ...
Breaking Biology Technology:
Cached News: